县监狱阿片类使用障碍药物治疗——释放后结局
2019年美国马萨诸塞州7所县监狱启动试点,为所有阿片类使用障碍(OUD)羁押人员提供所有FDA批准的阿片类使用障碍药物(MOUD)。本观察性研究链接州数据,纳入2019年9月1日至2020年12月31日期间可能患OUD的6400人,其中2711人(42.4%)在监狱内接受MOUD、3689人(57.6%)未接受。经倾向评分加权及基线协变量调整后,监狱内接受MOUD与释放后30天内接受MOUD的可能性更高相关(调整相对风险1.44;95%CI 1.38–1.50),并与释放后致死性过量(调整风险比0.48;95%CI 0.36–0.64)、非致死性过量(调整风险比0.76;95%CI 0.68–0.85)、全因死亡(调整风险比0.44;95%CI 0.35–0.56)和再入狱(调整风险比0.88;95%CI 0.81–0.94)风险更低相关;两组住院发生率无实质差异。
要点
- 监狱内接受MOUD者释放后30天内接受MOUD的比例为60.2%,未接受者为17.6%(调整相对风险1.44;95%CI 1.38–1.50)。
- 监狱内接受MOUD与释放后致死性过量风险更低相关(调整风险比0.48;95%CI 0.36–0.64)。
- 监狱内接受MOUD与释放后全因死亡风险更低相关(调整风险比0.44;95%CI 0.35–0.56)。
- 监狱内接受MOUD与释放后非致死性过量(调整风险比0.76;95%CI 0.68–0.85)和再入狱(调整风险比0.88;95%CI 0.81–0.94)风险更低相关。
- 接受MOUD者中仅50.4%在释放后前90天中有75%的时间坚持MOUD治疗,57.5%在180天时仍在接受MOUD。
适用人群与场景
- 2019年9月1日至2020年12月31日期间马萨诸塞州7所县监狱中可能患阿片类使用障碍(OUD)的羁押人员。
- 研究队列共6400人:2711人(42.4%)在监狱内接受MOUD,3689人(57.6%)未接受。
处置流程与药物剂量
- 监狱内接受的MOUD为所有FDA批准的药物:接受治疗者中67.9%使用丁丙诺啡,25.7%使用美沙酮,6.5%使用纳曲酮。
研究设计与关键结果
- 研究类型为观察性研究,使用链接的州数据,比较监狱内接受与未接受MOUD者释放后MOUD接受、过量、死亡和再入狱情况。
- 队列6400人,2711人(42.4%)在监狱内接受MOUD,3689人(57.6%)未接受;接受者中67.9%用丁丙诺啡、25.7%用美沙酮、6.5%用纳曲酮。
- 接受MOUD者较未接受者更可能为白人(75.4% vs. 58.1%)、已被判刑(31.6% vs. 13.2%)、入狱时已在接受MOUD(73.7% vs. 17.1%)。
- 释放后30天内接受MOUD:接受组60.2% vs. 未接受组17.6%,调整相对风险1.44(95%CI 1.38–1.50)。
- 释放后致死性过量:调整风险比0.48(95%CI 0.36–0.64);非致死性过量:调整风险比0.76(95%CI 0.68–0.85)。
- 释放后全因死亡:调整风险比0.44(95%CI 0.35–0.56);再入狱:调整风险比0.88(95%CI 0.81–0.94)。
- 两组住院发生率无实质差异;接受MOUD者中50.4%在释放后前90天中有75%的时间坚持MOUD治疗,57.5%在180天时仍在接受MOUD。
证据类型、等级与局限
- 证据类型:观察性研究,使用链接州数据,采用对数二项模型和比例风险模型,并调整倾向评分权重及倾向评分加权后仍不平衡的基线协变量。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在监狱内接受MOUD与释放后MOUD启动可能性增加、过量、全因死亡和再入狱风险降低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).
METHODS: This observational study used linked state data to examine postrelease MOUD receipt, overdose, death, and reincarceration among persons with probable opioid use disorder (OUD) in carceral settings who did or did not receive MOUD from these programs from September 1, 2019, through December 31, 2020. Log-binomial and proportional-hazards models were adjusted for propensity-score weights and baseline covariates that remained imbalanced after propensity-score weighting.
RESULTS: The study cohort included 6400 persons with probable OUD: 2711 (42.4%) received MOUD in jail and 3689 (57.6%) did not. Among persons treated with MOUD in jail, 67.9% received buprenorphine, 25.7% received methadone, and 6.5% received naltrexone. Treated persons were more likely than those not treated to be White (75.4% vs. 58.1%), to be sentenced (31.6% vs. 13.2%), to be receiving MOUD at jail entry (73.7% vs. 17.1%), and to receive MOUD during the first 30 days after community release (60.2% vs. 17.6%; adjusted relative risk, 1.44; 95% confidence interval [CI], 1.38 to 1.50). Only 50.4% of MOUD recipients engaged in MOUD treatment for 75% of the first 90 days after release, and 57.5% were receiving MOUD at 180 days. Receipt of MOUD in jail, as compared with no such receipt, was associated with lower postrelease risks of fatal overdose (adjusted hazard ratio, 0.48; 95% CI, 0.36 to 0.64), nonfatal overdose (adjusted hazard ratio, 0.76; 95% CI, 0.68 to 0.85), death from any cause (adjusted hazard ratio, 0.44; 95% CI, 0.35 to 0.56), and reincarceration (adjusted hazard ratio, 0.88; 95% CI, 0.81 to 0.94). The incidence of hospitalizations did not differ substantially between the two groups.
CONCLUSIONS: Receipt of MOUD in jail was associated with an increased likelihood of postrelease MOUD initiation and decreased risks of overdose, death from any cause, and reincarceration. (Funded by the National Institutes of Health and others.).
参考来源
- Friedmann PD, Wilson D, Stopka TJ, et al. Medications for Opioid Use Disorder in County Jails - Outcomes after Release. N Engl J Med. 2025. PMID: 40929634. doi:10.1056/NEJMsa2415987
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。